Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Coll Camenforte, Sergi, 1991-
- dc.contributor.author Matabosch Geronès, Xavier
- dc.contributor.author Llorente Onaindia, Jone
- dc.contributor.author Carbó Banús, Marcel·lí
- dc.contributor.author Pérez Mañá, Clara
- dc.contributor.author Monfort Mercader, Núria, 1983-
- dc.contributor.author Monfort, Jordi
- dc.contributor.author Ventura Alemany, Rosa
- dc.date.accessioned 2020-02-24T08:04:44Z
- dc.date.issued 2019
- dc.description.abstract Triamcinolone hexacetonide (THA) is a synthetic glucocorticoid (GC) used by intra-articular (IA) administration. GCs are prohibited in sports competitions by systemic routes, and they are allowed by other routes considered of local action (IA administration, among others). The aim of the present work was to study the metabolic profile of THA in urine and plasma following IA administration. Eight patients (4 males and 4 females) with knee osteoarthritis received an IA dose of THA (40 mg) in the knee joint. Spot urine and plasma samples were collected before injection and at different time periods up to day 23 and 10 post-administration, respectively. The samples were analysed by liquid chromatography-tandem mass spectrometry. Neither THA nor specific THA metabolites were detected in urine. Triamcinolone acetonide (TA) and 6β-hydroxy-triamcinolone acetonide were the main urinary metabolites. Maximum concentrations wereobtained between 24 and 48 h after administration. Using the reporting level of 30 ng/mL to distinguish allowed from forbidden administrations of GCs, a large number of false adverse analytical findings would be reported up to day 4. On the other hand, TA was detected in all plasma samples collected up to day 10 after administration. THA was also detected in plasma but at lower concentrations. The detection of plasma THA would be an unequivocal proof to demonstrate IA use of THA. A reversible decrease was observed in plasma concentrations of cortisol in some of the patients, indicating a systemic effect of the drug.
- dc.format.mimetype application/pdf
- dc.identifier.citation Coll S, Matabosch X, Llorente-Onaindia J, Carbó ML, Pérez-Mañá C, Monfort N et al. Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration. Drug Test Anal. 2019 Nov;11(11-12):1589-600. DOI: 10.1002/dta.2614
- dc.identifier.doi http://doi.org/10.1002/dta.2614
- dc.identifier.issn 1942-7603
- dc.identifier.uri http://hdl.handle.net/10230/43686
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof Drug Testing and Analysis. 2019 Nov;11(11-12):1589-600
- dc.rights This is the peer reviewed version of the following article: Coll S, Matabosch X, Llorente-Onaindia J, Carbó ML, Pérez-Mañá C, Monfort N. et al. Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration. Drug Test Anal. 2019 Nov; 11 (11-12):1589-1600, which has been published in final form at http://dx.doi.org/10.1002/dta.2614. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.keyword Adverse analytical finding
- dc.subject.keyword Doping
- dc.subject.keyword Glucocorticoids
- dc.subject.keyword Triamcinolone hexacetonide
- dc.title Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/acceptedVersion